Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | IL1RN | P18510 | 1/20 | 0.47 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | MMP7 | P09237 | 1/20 | 0.44 |
| ▸ | MMP14 | P50281 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1122298 | 0.84 | CA2 (0.52) | HPGDLMNACA1CA2KMT2A | |
| SCHEMBL10772858 | 0.84 | HPGD (0.53) | HPGDLMNAKEAP1CA1CA2 | |
| SCHEMBL4401320 | 0.84 | CA1 (0.50) | HPGDLMNAKEAP1CA1CA2 | |
| SCHEMBL6665659 | 0.82 | CA1 (0.50) | HPGDLMNACA1CA2KMT2A | |
| SCHEMBL6202161 | 0.82 | HPGD (0.56) | HPGDLMNAKEAP1CA1CA2 | |
| SCHEMBL830095 | 0.82 | CA1 (0.50) | HPGDLMNACA1CA2KMT2A | |
| SCHEMBL832208 | 0.81 | HPGD (0.50) | HPGDLMNAKEAP1CA1CA2 | |
| SCHEMBL2557584 | 0.80 | HPGD (0.65) | HPGDLMNACA1CA2KMT2A | |
| SCHEMBL1122574 | 0.80 | CA1 (0.56) | CA1CA2KMT2ACA12CA9 | |
| SCHEMBL829810 | 0.78 | CA1 (0.54) | HPGDLMNACA1CA2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143428-B2 | Heteroaryl sulfones and sulfonamides and therapeutic uses thereof | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2012-03-27 | — | — | US | disclosed |
| EP-1534284-B1 | AMINO-SUBSTITUTED SULFONANILIDES AND DERIVATIVES THEREOF FOR TREATING PROLIFERATIVE DISORDERS | UNIV TEMPLE (US) | 2011-07-27 | — | — | EP | disclosed |
| US-20070232649-A1 | Heteroaryl Sulfones and Sulfonamides and Therapeutic Uses Thereof | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2007-10-04 | — | — | US | disclosed |
| EP-1765804-A2 | HETEROARYL SULFONES AND SULFONAMIDES AND THERAPEUTIC USES THEREOF | Temple University of the Commonwealth System of Higher Education (US) | 2007-03-28 | — | — | EP | disclosed |
| US-7161031-B2 | Amino-substituted sulfonanilides and derivatives thereof for treating proliferative disorders | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2007-01-09 | — | — | US | disclosed |
| EP-1534284-A4 | AMINO-SUBSTITUTED SULFONANILIDES AND DERIVATIVES THEREOF FOR TREATING PROLIFERATIVE DISORDERS | UNIV TEMPLE (US) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005123077-A2 | HETEROARYL SULFONES AND SULFONAMIDES AND THERAPEUTIC USES THEREOF | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2005-12-29 | — | — | WO | disclosed |
| EP-1534284-A2 | AMINO-SUBSTITUTED SULFONANILIDES AND DERIVATIVES THEREOF FOR TREATING PROLIFERATIVE DISORDERS | Temple University of the Commonwealth System of Higher Education (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20050096484-A1 | Amino-substituted sulfonanilides and derivatives thereof for treating proliferative disorders | ONCONOVA THERAPEUTICS, INC. | 2005-05-05 | — | — | US | disclosed |
| EP-0971908-B1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2004-06-30 | — | — | EP | disclosed |
| WO-2003072063-A2 | AMINO-SUBSTITUTED SULFONANILIDES AND DERIVATIVES THEREOF FOR TREATING PROLIFERATIVE DISORDERS | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2003-09-04 | — | — | WO | disclosed |
| US-6436927-B1 | 8-UREIDO AND 8-THIOUREIDO 2,1-BENZOTHIAZINE 2,2-DIOXIDES | SMITHKLINE BEECHAM CORPORATION | 2002-08-20 | — | — | US | disclosed |
| EP-0971908-A4 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM (US) | 2000-05-17 | — | — | EP | disclosed |
| EP-0971908-A1 | IL-8 RECEPTOR ANTAGONISTS | Smithkline Beecham (US) | 2000-01-19 | — | — | EP | disclosed |
| WO-1998034929-A9 | IL-8 RECEPTOR ANTAGONISTS | — | 1999-01-07 | — | — | WO | disclosed |
| WO-1998034929-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232649-A1 | Heteroaryl Sulfones and Sulfonamides and Therapeutic Uses Thereof | SULT1E1, STS, CCNE1 | HPGD 3143/4885LMNA 2758/4885KEAP1 2999/4885 |
| US-20050096484-A1 | Amino-substituted sulfonanilides and derivatives thereof for treating proliferative disorders | ARSA, MKI67, CCNA1 | HPGD 2647/4885LMNA 2497/4885KEAP1 1688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.